R
Robert Radinsky
Researcher at Amgen
Publications - 137
Citations - 12771
Robert Radinsky is an academic researcher from Amgen. The author has contributed to research in topics: Metastasis & Panitumumab. The author has an hindex of 47, co-authored 136 publications receiving 12342 citations. Previous affiliations of Robert Radinsky include University of Texas MD Anderson Cancer Center & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado,Michael S. Wolf,Marc Peeters,Eric Van Cutsem,Salvatore Siena,Daniel J. Freeman,Todd Juan,Robert Sikorski,Sid Suggs,Robert Radinsky,Scott D. Patterson,David D. Chang +11 more
TL;DR: Panitumumab monotherapy efficacy in mCRC is confined to patients with WT KRAS tumors, and KRAS status should be considered in selecting patients withmCRC as candidates for panitumuab mon Therapy.
Journal Article
Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice.
Paul Perrotte,Takashi Matsumoto,Keiji Inoue,Hiroki Kuniyasu,Beryl Y. Eve,Daniel J. Hicklin,Robert Radinsky,Colin P.N. Dinney +7 more
TL;DR: Therapy with anti-EGFR MAb C225 has a significant antitumor effect mediated, in part, by inhibition of angiogenesis, and down-regulation of these angiogenic factors preceded the involution of blood vessels.
Journal Article
Blockade of the Epidermal Growth Factor Receptor Signaling by a Novel Tyrosine Kinase Inhibitor Leads to Apoptosis of Endothelial Cells and Therapy of Human Pancreatic Carcinoma
Christiane J. Bruns,Carmen C. Solorzano,Matthew T. Harbison,Shutaro Ozawa,Rachel Tsan,Dominic Fan,James L. Abbruzzese,Peter Traxler,Elisabeth Buchdunger,Robert Radinsky,Isaiah J. Fidler +10 more
TL;DR: It is demonstrated that oral administration of an EGF-R tyrosine kinase inhibitor decreased growth and metastasis of human pancreatic cancer growing orthotopically in nude mice and increased survival.
Journal ArticleDOI
Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2.
Jonathan D. Oliner,Hosung Min,Juan Leal,Dongyin Yu,Shashirekha Rao,Edward You,Xiu Tang,Haejin Kim,Susanne Meyer,Seog Joon Han,Nessa Hawkins,Robert Rosenfeld,E. Davy,Kevin Graham,Frederick W. Jacobsen,Shirley Stevenson,Joanne Ho,Qing Chen,Thomas Hartmann,Mark Leo Michaels,Michael J. Kelley,Luke Li,Karen C. Sitney,Frank Martin,Ji-Rong Sun,Nancy Zhang,John Lu,Juan Estrada,Rakesh Kumar,Angela Coxon,Stephen Kaufman,James Pretorius,Sheila Scully,Russ Cattley,Marc Payton,Steve Coats,Linh Nguyen,Binodh DeSilva,Anthony Ndifor,Isaac J. Hayward,Robert Radinsky,Tom Boone,Richard Kendall +42 more
TL;DR: In this paper, the authors showed that specific Ang2 inhibition may represent an effective anti-angiogenic strategy for treating patients with solid tumors, and they showed that anti-Ang2 therapy also prevented VEGF-stimulated neovascularization in a rat corneal model of angiogenesis.
Journal Article
Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
Christiane J. Bruns,Matthew T. Harbison,Darren W. Davis,Charles A. Portera,Rachel Tsan,David J. McConkey,Douglas B. Evans,James L. Abbruzzese,Daniel J. Hicklin,Robert Radinsky +9 more
TL;DR: Experiments indicate that therapeutic strategies targeting EGF-R have a significant antitumor effect on human L3.6pl pancreatic carcinoma growing in nude mice which is mediated in part by inhibition of tumor-induced angiogenesis, leading to tumor cell apoptosis and regression.